CALA Company Profile and Key Details

Calithera Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended March 30, 2023, missed forecasts by -4.7%. The prior quarter beat by 1.01%. Over the last six quarters, Apple has recorded several small beats. These include -34.78% in November 09, 2021.

Calithera Biosciences, Inc. has 4.87 million shares outstanding. The public float is 4.83 million shares, elevated short interest at 8.92% of float. This equals 417.28 thousand shares. The short ratio is 0.78 days. Institutional investors hold 0.0% of the float. Insiders own 1.07%. ADAGE CAPITAL PARTNERS GP, L.L.C. holds 3.55 million shares, ADAGE CAPITAL PARTNERS GP LLC has 3.14 million shares and MORGENTHALER VENTURE PARTNERS IX LP has 2.16 million shares.

Calithera Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.91. This means the shares are trading below this model’s fair value.

The stock is currently trading near its 52-week low $0.00 and $0.00. With a market capitalization of about $487.00, Calithera Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.25). Key stats such as the average daily volume over the past year has been around 180.00 shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Calithera Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stephanie Wong, the company employs approximately 8 people and listed since October 02, 2014. Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023.

Calithera Biosciences, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at -0.0, also above market averages.

Our AI price prediction model suggests that Calithera Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by August 20, 2026, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by November 04, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 06, 2027, within a range of $0.00 to $0.04.

Calithera Biosciences, Inc. (NASDAQ:CALA) shares are flat 0.0% year-to-date Short-term momentum has been flat over the last quarter, despite recent volatility. Valuation shows Calithera Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.0. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.